KRAS G12C clinical trials at UCSD

1 research study open to eligible people

BBO-8520 in Adult Subjects with KRASG12C Non-small Cell Lung and Colorectal Cancer
open to eligible people ages 18 years and up
A first in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer and colorectal cancer
La Jolla, California and other locations

Last updated: October 28, 2024